Completed
PHASE3
INTERVENTIONAL
NCT02204163
Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Evaluate the efficacy and safety after treatment of Eutropin® inj. compared to Genotropin® in infants/toddlers with Prader-Willi syndrome
Interventions
Name:
Eutropin
Type:
DRUG
Description:
Name:
Genotropin
Type:
DRUG
Description:
Primary Outcomes
Measure:
Change from baseline in height SDS (Standard Deviation Score)
TimeFrame:
baseline and 52 weeks
Description:
Measure:
Change from baseline in Lean body mass (g)
TimeFrame:
baseline and 52 weeks
Description:
Measure:
Change from baseline in Percent body fat (%)
TimeFrame:
baseline and 52 weeks
Description:
Trial Information
NCT ID
NCT02204163
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
LG Life Sciences
Last Updated
December 15, 2025